ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Helius Medical Technologies Inc

Helius Medical Technologies Inc (HSDT)

0.4874
0.0174
(3.70%)
Al cierre: 18 Diciembre 3:00PM
0.425
-0.0624
( -12.80% )
Fuera de horario: 5:46PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
0.425
Postura de Compra
0.4462
Postura de Venta
0.5097
Volume Operado de la Acción
70,605
0.47 Rango del Día 0.5097
0.373 Rango de 52 semanas 9.50
Capitalización de Mercado [m]
Precio Anterior
0.47
Precio de Apertura
0.4861
Última hora de negociación
16:00:03
Volumen financiero
US$ 34,861
Precio Promedio Ponderado
0.493752
Volumen promedio (3 m)
367,806
Acciones en circulación
3,728,172
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.20
Beneficio por acción (BPA)
-2.37
turnover
644k
Beneficio neto
-8.85M

Acerca de Helius Medical Technologies Inc

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Ne... Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. The company derives its revenue from Product Sales, fees and; license sources. Mostrar más

Sector
Electromedical Apparatus
Industria
Electromedical Apparatus
Sede
Vancouver, British Columbia, Can
Fundado
-
Helius Medical Technologies Inc is listed in the Electromedical Apparatus sector of the NASDAQ with ticker HSDT. The last closing price for Helius Medical Technolog... was US$0.47. Over the last year, Helius Medical Technolog... shares have traded in a share price range of US$ 0.373 to US$ 9.50.

Helius Medical Technolog... currently has 3,728,172 shares in issue. The market capitalisation of Helius Medical Technolog... is US$1.75 million. Helius Medical Technolog... has a price to earnings ratio (PE ratio) of -0.20.

HSDT Últimas noticias

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic...

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from...

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI scores from Phase 1 to end of treatment at week 14 -- -- Confirms...

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today...

Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results

NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.164-27.8438030560.5890.5890.4251206610.51146062CS
4-0.0404-8.680704770090.46540.75510.41512451350.58115229CS
12-0.335-44.07894736840.760.7610.3733678060.5492306CS
26-0.605-58.73786407771.031.23990.3732938040.68041291CS
52-7.075-94.33333333337.59.50.3733344582.79693481CS
156-268.075-99.8417132216268.52980.37376407231.95748377CS
260-769.575-99.944805194877029400.373597376266.42635472CS

HSDT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Helius Medical Technolog...?
El precio actual de las acciones de Helius Medical Technolog... es US$ 0.425
¿Cuántas acciones de Helius Medical Technolog... están en circulación?
Helius Medical Technolog... tiene 3,728,172 acciones en circulación
¿Cuál es la capitalización de mercado de Helius Medical Technolog...?
La capitalización de mercado de Helius Medical Technolog... es USD 1.75M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Helius Medical Technolog...?
Helius Medical Technolog... ha negociado en un rango de US$ 0.373 a US$ 9.50 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Helius Medical Technolog...?
El ratio precio/beneficio de Helius Medical Technolog... es -0.2
¿Cuál es el ratio de efectivo a ventas de Helius Medical Technolog...?
El ratio de efectivo a ventas de Helius Medical Technolog... es 2.78
¿Cuál es la moneda de reporte de Helius Medical Technolog...?
Helius Medical Technolog... presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Helius Medical Technolog...?
El último ingresos anual de Helius Medical Technolog... es USD 644k
¿Cuál es el último beneficio anual de Helius Medical Technolog...?
El último beneficio anual de Helius Medical Technolog... es USD -8.85M
¿Cuál es la dirección registrada de Helius Medical Technolog...?
La dirección registrada de Helius Medical Technolog... es SUITE 1980, 1075 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA, V6E 3C9
¿En qué sector industrial opera Helius Medical Technolog...?
Helius Medical Technolog... opera en el sector ELECTROMEDICAL APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CURRCurrenc Group Inc
US$ 7.58
(279.00%)
3.21M
APCXAppTech Payments Corporation
US$ 0.635
(66.67%)
3.1M
ELABElevai Labs Inc
US$ 3.21
(49.30%)
1.42M
DALNDallasNews Corporation
US$ 6.80
(39.63%)
40.16k
FTELFitell Corporation
US$ 9.70
(38.57%)
321.05k
LITMSnow Lake Resources Ltd
US$ 0.492
(-39.96%)
11.13M
MUUDirexion Daily MU Bull 2X Shares
US$ 16.65
(-32.15%)
671.54k
MULLGranite Shares 2x Long MU Daily ETF
US$ 14.90
(-31.87%)
47.47k
AEMDAethlon Medical Inc
US$ 0.50
(-24.31%)
6.74M
AMODAlpha Modus Holdings Inc
US$ 2.15
(-16.99%)
10.16k
LCIDLucid Group Inc
US$ 2.50
(-1.19%)
37.41M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.367
(0.60%)
17M
NVDANVIDIA Corporation
US$ 131.13
(1.72%)
13.19M
MUMicron Technology Inc
US$ 87.421
(-15.86%)
12.36M
LITMSnow Lake Resources Ltd
US$ 0.492
(-39.96%)
11.13M

HSDT Discussion

Ver más
Monksdream Monksdream 2 meses hace
HSDT new 52 week low
👍️0
Awl416 Awl416 2 meses hace
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
👍️0
Banjo50 Banjo50 4 meses hace
IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!
👍️0
Monksdream Monksdream 5 meses hace
HSDT new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
HSDT new 52 week low
👍️0
Jeremiah 777 Jeremiah 777 7 meses hace
company received HCPCS codes and CMS reimbursement. They also sign up VA distributor.
Blue Cross is reimbursing
👍️0
Monksdream Monksdream 7 meses hace
HSDT new 52 lo
👍️0
Monksdream Monksdream 7 meses hace
HSDT new 52 week
👍️0
Monksdream Monksdream 8 meses hace
HSDT new 52+ low
👍️0
Awl416 Awl416 8 meses hace
Pop
👍️0
subslover subslover 9 meses hace
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) --
-- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually --

NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services (“Lovell”), an SBA-certified Service Disabled Veteran Owned Small Business (“SDVOSB”), to make the Company’s Portable Neuromodulation Stimulator (“PoNS®”) device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

“Through their Multiple Sclerosis Centers of Excellence, the VA is dedicated to maximizing the quality of life for veterans suffering from MS, and we are thrilled to partner with Lovell to expand the reach of our innovative PoNS device. In a study of real-world results, after 14 weeks of PoNS Therapy, 100% of MS patients experienced a clinically meaningful improvement in gait. More than 28,000 cases of MS are reported to the VA annually, making PoNS a potential game changer for veterans and their families,” said Dane Andreeff, President and Chief Executive Officer of Helius.

“As the largest integrated healthcare system in the U.S., the VA provides services to veterans with MS from the time of diagnosis through the rest of their lives. Veterans have given their best to our country and should have access to the most innovative and effective resources available. Lovell is proud to introduce this important product to the VA and other federal healthcare providers,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

“Recently, Helius highlighted the real-life story of Kevin Byrne, a retired U.S. veteran who’s been suffering from MS since 1999. Gait difficulties had taken away his most valued treasure, quality adventures with his 13-year-old daughter, but PoNS Therapy helped him improve his walking by increasing speed, endurance, and distance. After treatment with PoNS, he was able to take his daughter to New York City, where they enjoyed walking the streets and seeing Broadway shows, experiences he thought were lost forever. While clinical results have demonstrated the effectiveness of PoNS Therapy, it’s firsthand accounts like Captain Byrne’s that are the most gratifying,” concluded Andreeff.
👍️0
TheFinalCD TheFinalCD 9 meses hace
https://finviz.com/quote.ashx?t=HSDT&ty=c&ta=1&p=d

https://twitter.com/health_stocks/status/1775480375587811622

$hsdt 7.72
👍️0
BurgerKing82 BurgerKing82 9 meses hace
Besides SS...anything promising about this 1?
👍️0
Invest-in-America Invest-in-America 10 meses hace
HSDT: So-called "Medical Research" firms producing NONSENSE gadgets like this should be put in DEATH CAMPS --- along with the 'inventor' of the "NAVAGE" garden hose up one's NOSE!! They are MORONS!! (Fix the UNDERLYING physiological-cellular-GENOMIC problems, you Homo sapiens SHITHEADS!!!)
👍️0
Invest-in-America Invest-in-America 10 meses hace
HSDT: I wouldn't want THAT absurd gadget in my MOUTH, anymore than I'd want a "NAVAGE" in my NOSE, nor up my ASS!!! (What a Medically-IGNORANT Planet we all live on!!!!)
👍️0
TheFinalCD TheFinalCD 10 meses hace
HSDT https://twitter.com/health_stocks/status/1764622834007962029
👍️0
Awl416 Awl416 10 meses hace
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
👍️0
subslover subslover 10 meses hace
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) --

-- Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash runway into the third quarter 2024 --

NEWTOWN, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has assigned Healthcare Common Procedure Coding System (“HCPCS”) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each” to describe the PoNS mouthpiece. The new HCPCS codes will be effective April 1, 2024.

“PoNS Therapy® is life-changing for people who suffer gait impairment due to MS and we’re pleased that CMS understood the benefits of this innovative treatment by establishing HCPCS codes for both the PoNS mouthpiece and controller. This marks a critical reimbursement and access milestone and provides Helius the ability to begin negotiating reimbursement with third-party payers using these unique HCPCS codes. We believe there is a reasonable likelihood that at the public meetings this summer CMS will determine a reimbursement amount for each of the PoNS controller and mouthpiece to take effect on October 1, 2024,” stated Helius’ President and Chief Executive Officer, Dane Andreeff.

“As we pursue widespread reimbursement for PoNS Therapy, we have continued to manage our cash burn. With the recently announced $1.5 million of net proceeds from the sale of shares of our common stock under our ATM program at an average share price of $9.17 per share, our cash runway has been extended into the third quarter of this year. Once we establish reimbursement for PoNS, we believe we will be able to expand reimbursement across third-party payers and have a pathway to positive cash flow as we continue to pursue authorization for stroke in the U.S.,” concluded Andreeff.

PoNS is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program. The Company is also seeking marketing authorization under PoNS’s breakthrough designation for stroke in the United States, where over five million stroke survivors are affected by walking and balance disability. In Canada, PoNS is authorized to treat balance impairment due to MS, stroke and mild-to-moderate traumatic brain injury.

About Helius Medical Technologies, Inc.
👍️0
Monksdream Monksdream 10 meses hace
The pr pump then the dump
👍️0
subslover subslover 10 meses hace
As of November 3, 2023, the registrant had 708,247 shares of Class A common stock, $0.001 par value per share, outstanding.
👍️0
TheFinalCD TheFinalCD 10 meses hace
traded it but made very little money

feels wonky
👍️0
subslover subslover 10 meses hace
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients --

-- Interaction with FDA on clinical program feasibility streamlines cost and timeline and leverages trials with the Medical University of South Carolina and Brooks Rehabilitation --

-- Studies and real-world evidence results will be submitted for regulatory authorization under PoNS’s breakthrough designation for stroke --

-- Regulatory submission for stroke and marketing authorization expected in 2025 --

NEWTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors. Helius’ registrational program includes two controlled studies. The clinical program will leverage a randomized, controlled, double blinded investigator-initiated trial (“IIT”), led by Dr. Steven Kautz at the Medical University of South Carolina (“MUSC”) and a Company-sponsored study to enroll approximately 100 subjects. Dr. Kautz’s IIT began enrollment of 60 participants in September 2023 with the collaboration of Dr. Mark Bowden at Brooks Rehabilitation as a second site.

“Vetting the registrational program and design of our clinical studies with the FDA is an important milestone for Helius and meeting the agency’s expectations will give us the most efficient path to delivering PoNS Therapy to stroke patients,” said Dr. Antonella Favit-Van Pelt, Helius’ Chief Medical Officer. “This development plan, which leverages early study results and real-world evidence from Canada, allows us to streamline the size, timeline, and cost of the registrational program and positions Helius on the best course toward potential FDA authorization under PoNS’s breakthrough designation for stroke.”

When evaluated in a real-world evidence (RWE) database analysis of Canadian stroke patients with gait or balance deficit, PoNS Therapy demonstrated a significant and clinically meaningful improvement in gait, averaging a 6.74-point improvement in the functional gait assessment (FGA) score over a 14-wk treatment period (95% CI: 4.85 to 8.63). Before starting PoNS Therapy, over 93% of patients were considered at risk of falling, as determined by an FGA
👍️0
Awl416 Awl416 10 meses hace
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
👍️0
tw0122 tw0122 10 meses hace
Pump it up
👍️0
DollarDan DollarDan 1 año hace
I am guessing this is not the platform to talk about HSDT stock seeing as no one has been here for a while.
👍️0
ckmseven788 ckmseven788 1 año hace
Interesting. Hopefully they announce FDA approval and/or Medicaid coverage on PONS, or some kind news catalyst. There’s got to be a reason the CEO has been loading. Plus, this past Monday there was a major shift in dollar volume. 200 million dollars traded that day, then every day after that at least a couple million traded. HSDT has never even been close to volume like that. I got a feeling something is brewing.
👍️0
dinogreeves dinogreeves 1 año hace
They don't have much in the books, they are going to do it soon, they only had 8.5 million as of the end of June and each quarter goes by 3.5 million dollars negative in the books and 250,000 dollars in sales, that is nothing, yes true that they don't have any debt, but what else do they have to show for other that 250,000 dollars in sales, that is not enough to cover expenses. 15-20 is the target to get out, anything more than that you are asking for trouble.
👍️0
ckmseven788 ckmseven788 1 año hace
All it’s saying is they have the right to add more shares to the total shares outstanding if they choose. They shouldn’t have to do that since they have cash and zero debt, but even if they do one would think they would do it at a much higher PPS then here…
👍️0
dinogreeves dinogreeves 1 año hace
They have not been in effect yet.

https://www.sec.gov/Archives/edgar/data/1610853/000110465923064633/tm2315565-1_s3a.htm

https://www.sec.gov/Archives/edgar/data/1610853/000110465923074253/tm2319321-1_424b5.htm
👍️0
ckmseven788 ckmseven788 1 año hace
Can you post a link to this?
👍️0
tw0122 tw0122 1 año hace
Nice runner small float now
👍️0
dinogreeves dinogreeves 1 año hace
I jumped in yesterday on this, Tuesday could hit 15-20, At the Market prospectus has been filed a little while ago for close to 2 million dollars. I won't ask for anything more than 20. Good luck everyone.
👍️0
Jess070283 Jess070283 1 año hace
$20+ tomorrow IMO
👍️0
Awl416 Awl416 1 año hace
Bye bye float. The fact I got filled on the bid today. All about timing

TGIF - enjoy your long weekend all
👍️0
yankees18 yankees18 1 año hace
Has a few gaps to fill on the way up!!
👍️0
Awl416 Awl416 1 año hace
Fun isn’t it
👍️0
saj saj 1 año hace
Boom!
👍️0
TheFinalCD TheFinalCD 1 año hace
$HSDT RS https://finance.yahoo.com/news/helius-medical-technologies-announces-reverse-130000309.html

https://twitter.com/health_stocks/status/1691797717029151114
👍️0
heyitsmeagain heyitsmeagain 2 años hace
Sold
👍️0
heyitsmeagain heyitsmeagain 2 años hace
IS IT FINALLY TIME?
👍️0
kzivann kzivann 2 años hace
Premarket volume on news. PPS up a bit?

HSDT
👍️0
ckmseven788 ckmseven788 2 años hace
This one is looking good
👍️0
Imokhopeur Imokhopeur 2 años hace
Had to grab a few
👍️0
missile_systems missile_systems 2 años hace
OMG… Maine !
Sounds like a hidden gem Brother.
Never been that far north. I’m in the Philly / South Jersey area and our winters are no picnic but the area you mentioned is a whole other league LOLOL!!! The winters have to be brutal, but, if push comes to shove … that sounds like a great spot to bug out !!!!
Good night… talk soon.

mis
👍️0
subslover subslover 2 años hace
OMG brother you are so right on with that statement. I know a great location in NW Maine called Moosehead lake. just a few peps live there and it's so secluded that nobody knows how to get there. All the roads are dirt. I went there with my EX Wife years ago and stayed in a cabin on the lake. Many bears and Moose live there so you need their permission to stay. I can't imagine what the winters are like there. I don't even know if they have cell or internet service. lol
👍️0
subslover subslover 2 años hace
Very cool, I will respond back to your PM early Saturday. Email and phone #
👍️0
missile_systems missile_systems 2 años hace
Yes Sir my family and I are ok .
These certainly are worrisome times my friend.
A generator, some long term survival food and a shotgun or two are highly recommended.

Hopefully you and yours are ok and prepared as well.
God Bless !

mis
👍️0
missile_systems missile_systems 2 años hace
Thanks soo much my friend.
I will send you a d m on Friday happy hour ihub service.
Very much appreciate ya !!!!
👍️0
subslover subslover 2 años hace
Hello, my friend missile_systems! I would not chase this because it's very volitle. If she drops back to where she had been trading then maybe. I have several others I like so send me an email.
Hope you and yours are doing well in this day and age of uncertainty
👍️0
subslover subslover 2 años hace
Hello, my friend missile_systems! I would not chase this because it's very volitle. If she drops back to where she had been trading then maybe. I have several others I like so send me an email.
Hope you and yours are doing well in this day and age of uncertainty
👍️0

Su Consulta Reciente

Delayed Upgrade Clock